News Release - September 28, 2006

Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada

Source: Bristol-Myers Squibb

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.